No — and the international clinical consensus now positions CBT-I (Cognitive Behavioural Therapy for Insomnia), not sleeping pills, as the first-line treatment for chronic insomnia.

Every major sleep and medical body — the American Academy of Sleep Medicine, NICE (UK), the European Sleep Research Society, the Australasian Sleep Association — recommends CBT-I before medication for chronic insomnia, citing more durable effects and a far better risk profile (Edinger et al., Journal of Clinical Sleep Medicine, 2021 AASM clinical practice guideline; Riemann et al., Journal of Sleep Research, 2017/2023 ESRS guideline). Sleeping pills work for short-term sleep onset but do not address the mechanisms that maintain chronic insomnia, and tolerance develops within weeks for most agents. Used appropriately and short-term, they have a role; used as a long-term insomnia solution, they tend to perpetuate the very arousal pattern that keeps insomnia going.

This is not anti-medication — sometimes a short-term prescription is exactly the right tool. It is anti-using-medication-as-a-substitute-for-treatment. The clinical evidence is clear: address the mechanism, not just the symptom.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Yes — though the more common outcome is physical dependence, which is different from addiction but still produces meaningful withdrawal and rebound insomnia when stopping.

Two distinctions matter here:

• Physical dependence — your body adapts to the drug, so stopping produces withdrawal symptoms. It is extremely common with regular hypnotic use beyond 2–4 weeks and is essentially a normal pharmacological response.
• Addiction — compulsive use despite harm, dose escalation, drug-seeking behaviour. Less common, but it does occur, particularly with benzodiazepines, in people with a history of substance use disorder, and at higher doses.

NICE guidance (TA77) and the AASM both limit hypnotic prescribing to short courses — typically 2–4 weeks — specifically to manage these risks. Z-drugs (zopiclone, zolpidem) carry lower addiction potential than older benzodiazepines but the same dependence risk.

If you are wondering whether you are dependent versus addicted, that distinction is worth a conversation with your GP. Either way, the way out is the same: a gradual, supervised taper combined with CBT-I — and please don't stop abruptly, because rebound insomnia from a fast taper can be worse than what you started with.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Generally no — long-term use of prescription hypnotics is not recommended by any major sleep or medical body, because risks accumulate over time and 'safe' becomes increasingly contextual depending on age, comorbidities, and other medications.

Short-term use (a few weeks) is generally safe for most adults. With longer use, risks accumulate:

• Cognitive side effects (memory, attention, reaction time) — well-documented even at therapeutic doses
• Falls and hip fractures — clear dose-response relationships in epidemiological studies
• Tolerance — efficacy fades over months

The 2021 AASM clinical practice guideline (Edinger et al., Journal of Clinical Sleep Medicine, 2021) and the 2023 ESRS European Insomnia Guideline update (Riemann et al., Journal of Sleep Research, 2023) both restrict hypnotic prescribing to short-term courses — typically up to four weeks — for this reason, as does NICE. Newer agents (orexin receptor antagonists — daridorexant, lemborexant, suvorexant) appear to have better long-term safety profiles, and the 2023 ESRS guideline now lists daridorexant as suitable for longer-term use in selected patients.

'Safe' is contextual — for an older adult with falls risk, even short-term hypnotic use needs careful weighing; for a younger adult during a brief crisis, less of an issue. If you have been on sleeping pills long-term, please do not stop abruptly. The safe path is a slow, supervised taper combined with evidence-based insomnia therapy.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Common side effects across the prescription hypnotic class include next-day grogginess, memory and attention problems, impaired coordination, dependence with regular use, rebound insomnia on stopping, and increased fall risk — particularly in older adults.

How they differ by drug class

• Z-drugs (zopiclone, zolpidem) — metallic taste, next-day grogginess, and occasionally complex sleep behaviours such as sleep-walking, sleep-driving, or sleep-eating (uncommon but well-documented enough that the FDA added a black-box warning in 2019).
• Benzodiazepines (temazepam, diazepam) — longer half-lives and stronger amnestic effects, with cumulative cognitive impact and a particularly poor risk profile in older adults. Both the 2021 AASM guideline (Edinger et al., Journal of Clinical Sleep Medicine, 2021) and the 2023 ESRS guideline (Riemann et al., Journal of Sleep Research, 2023) recommend against routine benzodiazepine use for chronic insomnia.
• Orexin antagonists (suvorexant, lemborexant, daridorexant) — generally milder, but can cause daytime sleepiness and headache.

Side effects are not abstract — they are common and worth tracking. If you have started a hypnotic and are noticing daytime impairment, please tell your GP. Sometimes the side effects are doing more harm than the insomnia itself.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Because the brain adapts. With repeated exposure, receptor sensitivity changes (a process called tolerance), and the same dose produces progressively less sleep-promoting effect.

Hypnotic medications work by enhancing GABA-A receptor activity (Z-drugs, benzodiazepines) or by blocking orexin receptors (newer agents). With chronic exposure, the brain adjusts: receptor density changes, signalling alters, and the original effect diminishes. This is a normal pharmacological response, not a defect of the medication or the user. NICE prescribing guidance recommends short courses (typically 2–4 weeks) partly to stay ahead of this adaptation. Once tolerance has developed, increasing the dose tends to produce more side effects without restoring much of the original effect — and stopping abruptly often produces rebound insomnia that feels worse than where you started.

This is not failure on your part or on the medication's. It is biology. The way through is not chasing the next prescription, but addressing what is sustaining the insomnia in the first place — for which CBT-I has by far the strongest evidence.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Often yes — tolerance to hypnotics develops within weeks for most agents, and many people experience a gradual erosion of effect that prompts dose escalation, though this is not recommended for most agents.

Tolerance to the sedative effect of benzodiazepines and Z-drugs develops within 2–4 weeks of regular use; the AASM and NICE both highlight this as a primary reason for short-course prescribing. Escalating the dose to chase the original effect tends to deepen dependence without restoring the benefit, and increases side-effect risk. The newer orexin antagonists (suvorexant, lemborexant, daridorexant) appear to show less rapid tolerance in initial studies, though long-term real-world data is still maturing.

If you are finding yourself needing more to get the same effect, please talk to your GP. Dose escalation tends to be a stepping stone toward dependence rather than a route back to good sleep. CBT-I works alongside taper to break this loop.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

The short version: they differ by how selectively they act and how long they last.

• Benzodiazepines (temazepam, diazepam, lorazepam) — an older class with broad GABA-A receptor activity and longer half-lives.
• Z-drugs (zopiclone, zolpidem) — bind more selectively and were developed to reduce side effects.
• Orexin receptor antagonists (suvorexant, lemborexant, daridorexant) — the newest class, working through an entirely different mechanism.

Benzodiazepines were the dominant hypnotic class from the 1960s through the 1990s; their broad receptor activity produces sedation but also anxiolytic, muscle-relaxant, and amnestic effects, with longer-lasting next-day impairment and stronger dependence risk. Z-drugs were developed in the 1990s as more selective alternatives, with shorter half-lives and fewer next-day effects — though tolerance and dependence still develop. Orexin receptor antagonists work by blocking wake-promoting signals rather than enhancing sleep-promoting ones, producing more natural sleep architecture in trials, though they are expensive and not yet widely available on the NHS.

The class your prescription falls into matters for side-effect risk and taper strategy. If you're not sure which class you're on, ask your pharmacist — they will know in seconds.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

No — antihistamines like Nytol are not a clinically recommended treatment for chronic insomnia, and any sedating benefit they offer typically lasts only three to five nights before tolerance develops.

Diphenhydramine, the active ingredient in Nytol, blocks histamine H1 receptors in the brain to produce drowsiness as a side effect — but drowsiness is not the same as improved sleep architecture, and the drug does nothing to address what sustains chronic insomnia. Tolerance to the sedating effect develops rapidly (within three to five days of regular use), and rebound insomnia is common on stopping.

The side effects are significant:

• Next-day grogginess and dry mouth
• Urinary retention and constipation
• In older adults, anticholinergic effects that carry added risks — cognitive impairment and increased fall risk

No antihistamine is licensed in the UK as an insomnia treatment, and NICE does not recommend them for this purpose. If sleep problems are persistent, the approach worth pursuing is one that addresses what is actually sustaining the insomnia — not one that papers over a few nights and leaves you back where you started, often with side effects to boot.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

For acute insomnia in the very short term, yes — prescription hypnotics are more effective and better-studied than OTC options. For chronic insomnia, neither category is the right tool, and CBT-I outperforms both with a much better safety profile.

Prescription sleeping pills (Z-drugs, benzodiazepines, orexin antagonists) have undergone formal clinical trials, have known pharmacokinetics, and are dose-controlled. OTC options — primarily sedating antihistamines like diphenhydramine (Nytol) — have not been licensed as insomnia treatments in the UK and are not recommended by NICE for this purpose; tolerance to the sedating effect develops within 3–5 days. Neither category addresses the cognitive and behavioural mechanisms that sustain chronic insomnia, which is why both AASM (Edinger et al., JCSM, 2021) and NICE place CBT-I ahead of all medication.

'Better' depends on what you're trying to do. Bridge a one-off bad week? A short course of prescription hypnotic is reasonable. Treat ongoing insomnia? Neither over-the-counter nor prescription is the right tool — and the alternative actually works.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

This is a question for your GP — they will weigh your age, other medications, comorbidities, and the specific pattern of your insomnia, and any answer I give here cannot substitute for that assessment.

Prescribing decisions depend on several variables:

• Short-onset versus mid-night-waking insomnia (different half-lives suit different presentations)
• Age — risks shift markedly in older adults
• Other medications and comorbidities like sleep apnoea or depression
• Your prescribing history

The clinical landscape has shifted recently with the introduction of orexin receptor antagonists (daridorexant, lemborexant, suvorexant), which have arguably more favourable long-term profiles than traditional Z-drugs and benzodiazepines. Even so, the AASM clinical practice guideline (Sateia et al., Journal of Clinical Sleep Medicine, 2017) and NICE both maintain that CBT-I should be first-line for chronic insomnia.

If a GP is considering prescribing for you, ask: 'is CBT-I appropriate first?' For most chronic insomnia, the answer should be yes — and if your GP doesn't offer it, you can self-refer to a private sleep therapist or NHS Talking Therapies in many regions.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Some antidepressants are prescribed off-label for insomnia because of their sedating side effects — most commonly low-dose trazodone, amitriptyline, mirtazapine, or doxepin — but the evidence base is weaker than for licensed hypnotics, and they are not first-line.

The AASM clinical practice guideline (Sateia et al., Journal of Clinical Sleep Medicine, 2017) gave a 'weak' recommendation for low-dose doxepin specifically; other antidepressants used for sleep have even weaker formal evidence. These drugs are sometimes preferred over benzodiazepines or Z-drugs in patients with comorbid depression or anxiety, where the dual effect makes sense. Side effects vary by agent and can be significant — anticholinergic effects, weight gain, daytime sedation. As with all medication for chronic insomnia, the underlying behavioural and cognitive mechanisms remain untouched and tend to reassert themselves when medication stops.

If you're being offered an antidepressant primarily for sleep, ask your GP whether there is a sleep-specific reason for that choice. If the answer is mainly 'it makes people sleepy', that may not be the right reason on its own.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Anxiety medications (most commonly SSRIs or benzodiazepines) can reduce insomnia symptoms in people whose insomnia is driven primarily by an anxiety disorder — but they do not address the sleep-specific mechanisms that maintain chronic insomnia, and most are not licensed for sleep on their own.

SSRIs (sertraline, fluoxetine, citalopram) can paradoxically disrupt sleep in some people and improve it in others, depending on the individual's response. Benzodiazepines reduce anxiety and produce sedation but carry significant dependence risk with regular use. The bigger picture: CBT-I improves both sleep AND anxiety symptoms when used in comorbid presentations, often without separate anxiety treatment (Belleville et al., Clinical Psychology Review, 2011). Addressing the sleep side directly tends to unlock improvement in both.

Anxiety and insomnia feed each other, but they are not the same problem. If your sleep is the primary distressing symptom, addressing it directly with CBT-I often makes the anxiety considerably more manageable too — and avoids the dependence risks of long-term anxiolytic use.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

They work through entirely different mechanisms and address different problems — melatonin is a circadian-timing hormone, useful primarily for jet lag and shift work, while prescription sleeping pills are sedatives that reduce nervous-system activity to force sleep onset.

Melatonin is naturally produced by the pineal gland and signals 'biological night' to the body; supplemental melatonin works mainly by shifting the circadian rhythm forward or backward, which is why it is effective for jet lag, shift work, and delayed sleep phase disorder. Prescription sleeping pills (Z-drugs, benzodiazepines, orexin antagonists) act on different neural systems to suppress wakefulness or enhance sleep onset. The AASM clinical practice guideline (Sateia et al., Journal of Clinical Sleep Medicine, 2017) found weak evidence for melatonin in chronic insomnia, while CBT-I remains first-line.

Different tools for different jobs. If you're crossing time zones, melatonin is genuinely useful. If you have chronic insomnia, melatonin is unlikely to be the answer — and neither is a prescription sleeping pill.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Yes — melatonin interacts with several common medications and supplements, which is one reason 'because it's natural' is not a reason to assume it's safe with whatever else you're taking.

Melatonin can interact with:

• Anticoagulants (potentially increasing bleeding risk)
• Antihypertensives (potentially affecting blood pressure control)
• Immunosuppressants and diabetes medications
• Anticonvulsants and several CNS-active drugs

It is metabolised by liver enzymes (CYP1A2 in particular), which means medications affecting that enzyme — fluvoxamine, ciprofloxacin, oral contraceptives — can substantially change melatonin levels in the body. Drug-drug interaction risk is higher with high-dose unregulated OTC melatonin (often 5–10 mg, much higher than the 0.3–1 mg physiologic dose used in research) than with prescription regulated melatonin.

Before starting melatonin, please run it past your pharmacist with a list of everything else you take — including supplements. 'It's natural' does not mean 'it's safe in combination'. Your pharmacist will know the interactions in seconds.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

No — combining alcohol with sleeping pills meaningfully increases the risk of respiratory depression, complex sleep behaviours, falls, and overdose, and is contraindicated for every prescription hypnotic.

Both alcohol and hypnotic medications are CNS depressants; combining them produces additive (and sometimes synergistic) effects on breathing, coordination, and consciousness. The MHRA and FDA both warn against the combination explicitly. Specifically:

• With Z-drugs (zopiclone, zolpidem), alcohol increases the risk of complex sleep behaviours — sleep-walking, sleep-driving, sleep-eating.
• With benzodiazepines, the combination has been involved in a substantial proportion of accidental overdoses, particularly in older adults.

Alcohol itself also fragments sleep — it can hasten sleep onset but produces lighter, more disrupted sleep across the night. 'Just one glass with my zopiclone' is the situation that often becomes the problem. The risks accumulate quietly, particularly with regular use. If you're regularly mixing, please tell your GP — they can help you safely separate them.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

Probably not, if you've been taking them regularly for more than a few weeks — physical dependence develops within 2–4 weeks for most hypnotics, and stopping abruptly tends to produce rebound insomnia and other withdrawal symptoms.

Withdrawal severity depends on the agent, dose, and duration of use. Short half-life Z-drugs (zaleplon, zolpidem) produce more abrupt rebound; longer half-life benzodiazepines (diazepam, lorazepam) produce slower but more sustained withdrawal that can last weeks. Common withdrawal effects include:

• Severe rebound insomnia (often worse than the original problem)
• Anxiety, irritability, tremor, and sweating
• In rare cases — particularly with high-dose benzodiazepine use — seizures

NICE guidance recommends a gradual taper supervised by a GP for anyone on regular hypnotic use, typically over weeks to months rather than days. Please do not stop sleeping pills abruptly — particularly benzodiazepines, where abrupt cessation can be medically dangerous at higher doses. Your GP can plan a safe taper; combining the taper with CBT-I dramatically improves the long-term outcome.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

If you're on sleeping pills and want to stop, yes — and the best time to have that conversation is before you make any changes yourself.

Tapering hypnotics safely requires a structured plan: gradual dose reduction (typically 10–25% every 1–4 weeks, depending on the agent), often with substitution to a longer-half-life drug to ease withdrawal, and ideally combined with CBT-I to address the underlying insomnia. Stopping abruptly tends to produce rebound insomnia worse than the original problem, which usually drives people straight back to medication. Recent evidence supports combining taper with CBT-I and other multicomponent interventions: a 2025 BMJ systematic review and meta-analysis of 49 randomised trials with 39,336 participants (Zeraatkar et al., BMJ, 2025) found that multicomponent interventions — patient education, medication review, and CBT-I added to taper — meaningfully increased successful deprescribing versus usual care. The 2025 European expert consensus on switching and deprescribing hypnotic medications (Sleep Medicine, 2025) similarly recommends CBT-I alongside structured cross-tapering protocols.

This is one of the most useful conversations to have with your GP, and one of the most common things I help clients prepare for. A planned, gradual taper with CBT-I support is the most reliable path off sleeping pills — and most people are surprised how feasible it is.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.

With a gradual, GP-supervised taper combined with CBT-I — typically reducing the dose by 10–25% every 1–4 weeks, sometimes with substitution to a longer-half-life drug. Stopping abruptly is risky and frequently fails.

Safe tapering follows established protocols: gradual dose reduction over weeks to months (depending on the agent, dose, and duration of use), close monitoring for withdrawal, and parallel work on the underlying insomnia. Adding CBT-I to a taper improves outcomes — a 2025 BMJ systematic review and meta-analysis (Zeraatkar et al., n = 39,336) found that multicomponent interventions, including CBT-I added to taper, meaningfully increased successful deprescribing versus usual care, and the 2025 European expert consensus on hypnotic deprescribing (Sleep Medicine, 2025) recommends CBT-I alongside structured cross-tapering. For benzodiazepines specifically, substituting a short-acting agent with a longer-acting equivalent (e.g. diazepam) before tapering often eases the process. Abrupt discontinuation carries real risk — a 2023 JAMA Network Open analysis of 353,576 long-term benzodiazepine users (Maust et al., 2023) found small but meaningful increases in mortality and harm after unsupervised discontinuation, which is exactly why a planned taper matters.

The two questions worth asking your GP: 'Can we plan a taper?' and 'Can we add CBT-I alongside it?' Both together is the gold standard. If your GP doesn't offer CBT-I directly, you can self-refer to private sleep therapy or NHS Talking Therapies in many areas.

Important: this information is for general education and is not medical advice. Always check with your GP or pharmacist before starting, stopping or changing any medication or making any changes to your healthcare or lifestyle.